Co-Authors
This is a "connection" page, showing publications co-authored by GORDON B MILLS and FILIP JANKU.
Connection Strength
0.758
-
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
Score: 0.149
-
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404.
Score: 0.139
-
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
Score: 0.129
-
Correction to: Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2022 Jan; 41(3):460.
Score: 0.051
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
Score: 0.048
-
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann Oncol. 2019 04 01; 30(4):597-603.
Score: 0.042
-
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.040
-
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. 2016 05; 27(5):795-800.
Score: 0.034
-
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
Score: 0.033
-
Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
Score: 0.033
-
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
Score: 0.031
-
Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014 Apr; 45(4):701-8.
Score: 0.029